When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Last reviewed: 14 Mar 2025
Last updated: 04 Mar 2025

Summary

Definition

History and exam

Key diagnostic factors

  • presence of risk factors
  • older age
  • hepatomegaly

Other diagnostic factors

  • abdominal distension
  • oesophageal or gastric variceal bleeding
  • right upper quadrant abdominal pain
  • early satiety
  • weight loss
  • lower extremity oedema
  • hepatic encephalopathy
  • cachexia
  • jaundice
  • splenomegaly
  • asterixis
  • spider naevi
  • palmar erythema
  • periumbilical collateral veins
  • fetor hepaticus
  • diarrhoea
  • paraneoplastic syndrome
  • bone pain
  • severe abdominal pain
  • obstructive jaundice
  • enlarged haemorrhoidal veins
  • vascular bruit

Risk factors

  • cirrhosis
  • chronic hepatitis B (HBV) infection
  • chronic hepatitis C (HCV) infection
  • chronic heavy alcohol use
  • diabetes
  • obesity
  • family history of liver cancer
  • aflatoxin exposure
  • thorium dioxide radioactive contrast exposure
  • haemochromatosis
  • cigarette smoking
  • alpha-1-antitrypsin deficiency
  • porphyria cutanea tarda
  • primary biliary cholangitis (PBC)
  • primary sclerosing cholangitis (PSC)
  • use of androgenic steroids
  • use of oral contraceptives
  • male sex

Diagnostic investigations

1st investigations to order

  • full blood count
  • basic metabolic panel
  • liver function tests
  • prothrombin time/INR
  • viral hepatitis panel
  • alpha fetoprotein (AFP)
  • ultrasound of liver

Investigations to consider

  • contrast CT scan of abdomen
  • contrast MRI of abdomen
  • liver biopsy
  • computed tomography scan of chest
  • bone scan

Treatment algorithm

Contributors

Authors

Doan Y Dao, MD

Assistant Professor of Medicine

Director, Center of Excellence for Liver Disease in Vietnam

Johns Hopkins School of Medicine

Department of Medicine

Division of GI & Hepatology

Baltimore

MD

Disclosures

DYD receives grants from Roche, Fujifilm Medical System, and DELFI Diagnostics; serves as Guest Director of Hepatology for Tech University; and is a member of the Data and Safety Monitoring Board of IQVIA.

Ngoc-Thai Truong, MD, MS

Research Assistant

Vietnam Viral Hepatitis Alliance

Reston

VA

Disclosures

NTT declares that he has no competing interests.

Acknowledgements

Dr Doan Y Dao and Dr Ngoc-Thai Truong would like to gratefully acknowledge Dr Qingyao Daniel Huang, Dr Margaret Li Peng Teng, Dr Poh Seng Tan, Dr Badar Muneer, and Dr Smruti R. Mohanty, previous contributors to this topic.

Disclosures

QDH declares that he has no competing interests. MLPT declares that she has no competing interests. PST has received sponsorship/honorarium from Bayer (South East Asia) Pte Ltd and Sirtex for attending conferences, delivering lectures, and participating in advisory board meetings. BM declares that he has no competing interests. SRM serves as a speaker for Bristol-Myers Squibb regarding the use of entecavir for the treatment of chronic hepatitis B.

Peer reviewers

Srikrishna Nagri, MD

Gastroenterologist

Dartmouth-Hitchcock Nashua

Nashua

NH

Disclosures

SN declares that he has no competing interests.

Ned Snyder, MD, FACP

Professor of Medicine

Chief of Clinical Gastroenterology and Hepatology

University of Texas Medical Branch

Galveston

TX

Disclosures

NS declares that he has no competing interests.

Use of this content is subject to our disclaimer